Depo-Provera Birth Control Shot Lawsuit (Meningioma Tumors)
Depo-Provera, a commonly used injectable birth control shot, has been widely administered in the United States for decades. Approved by the FDA in 1992, Depo-Provera contains the synthetic hormone medroxyprogesterone acetate, which is injected every three months to prevent pregnancy. Its convenience and effectiveness have made it a popular choice for millions of women, but in recent years, serious health concerns have led to a surge in legal claims—especially related to the increased risk of meningioma, a type of brain tumor, and other hormone-driven complications.
Historic Context and Rising Use
Since its introduction, Depo-Provera has been particularly popular among women seeking a long-term, low-maintenance contraceptive method. The shot is most often administered in doctors’ offices, clinics, and community health centers. Over time, it has been promoted not just for birth control, but also for managing heavy periods, endometriosis, and other hormone-sensitive conditions.
In the early years after approval, most side effects reported were well known and relatively minor, such as changes in menstrual cycle, weight gain, and headaches. However, by the mid-2010s, a growing number of reports began to emerge linking Depo-Provera to more serious adverse effects, including osteoporosis, mood disorders, and—most concerning—meningioma, a usually benign but sometimes dangerous brain tumor.
Scientific and Legal Developments
Several peer-reviewed studies, primarily from Europe but also in the U.S., have found that long-term use of high-dose medroxyprogesterone acetate significantly increases the risk of developing meningioma. Meningiomas are tumors that form on the membranes covering the brain and spinal cord; while often benign, they can cause severe neurological symptoms, require surgery, and, in rare cases, become life-threatening.
In 2021, regulatory agencies in several countries, including France and the United Kingdom, moved to restrict or issue warnings about long-term or high-dose use of Depo-Provera. Soon after, the U.S. Food and Drug Administration updated Depo-Provera’s safety labeling to highlight the risk of meningioma, particularly after several years of continuous use.
These developments have led to a sharp increase in lawsuits filed in the United States. Plaintiffs allege that the manufacturer failed to adequately warn patients and healthcare providers about the true scope of risks—especially for long-term users and those with pre-existing risk factors for brain tumors. Many lawsuits also claim that doctors were not given sufficient information to screen for early signs of meningioma or to weigh alternative contraceptive methods.
Health Risks and Symptoms
The primary legal and medical concern is meningioma, but lawsuits also cite increased risks of:
- Breast cancer
- Blood clots (deep vein thrombosis, pulmonary embolism)
- Stroke
- Severe migraines and neurological symptoms
- Mood and personality changes
Symptoms that may prompt further medical evaluation in Depo-Provera users include persistent headaches, vision changes, seizures, memory loss, weakness, or other unexplained neurological issues. For some, diagnosis comes only after years of unexplained symptoms and multiple doctor visits.
Litigation Status and Settlements (2025 Update)
As of 2025, lawsuits against the manufacturer of Depo-Provera continue to grow, with claims being filed in both federal and state courts. Most cases are still in early discovery phases, with some consolidated into multidistrict litigation (MDL) to streamline proceedings and facilitate potential settlements.
Attorneys representing claimants are focused on obtaining internal documents from the manufacturer regarding what was known about meningioma risk, how side effects were reported, and whether earlier, stronger warnings could have prevented injuries. The outcome of these cases may hinge on the success of the earliest trials, which are expected to take place in 2025 and 2026.
While no global settlement has yet been announced as of this writing, legal experts believe that if the first bellwether trials result in substantial awards for plaintiffs, a broader settlement could follow for all affected claimants. Past pharmaceutical cases with similar risk profiles have produced settlement amounts ranging from tens of thousands to several hundred thousand dollars per claimant, depending on the severity and proof of injury.
Who Should Consider a Claim?
Women who used Depo-Provera for a year or more—especially those who used it for several consecutive years—and were later diagnosed with meningioma or other hormone-related tumors may be eligible to file a lawsuit. Families of women who died or suffered severe complications may also pursue claims on their behalf.
Key steps to strengthen a potential claim include:
- Obtaining a full medical history showing Depo-Provera use
- Securing pathology and imaging reports confirming meningioma or other tumors
- Documenting any related neurological, psychological, or quality-of-life impacts
- Collecting medical bills and proof of lost wages or career impact
Attorneys handling Depo-Provera cases generally offer free consultations and work on a contingency fee basis, meaning there are no upfront costs to claimants.
Current Outlook and Call to Action
Awareness of Depo-Provera’s risks is still growing, and many women remain unaware of the potential link between their symptoms and the shot. With ongoing litigation, media coverage, and medical research, the next few years will be critical for both justice and prevention. If you or a loved one used Depo-Provera and experienced brain tumors or other severe side effects, the time to act is now—lawsuit windows may close as settlements are negotiated.
